File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Tumor vaccine based on extracellular vesicles derived from γδ‐T cells exerts dual antitumor activities

TitleTumor vaccine based on extracellular vesicles derived from γδ‐T cells exerts dual antitumor activities
Authors
Keywordsextracellular vesicle
immunotherapy
tumor
vaccine
γδ-T cells
Issue Date31-Aug-2023
PublisherWiley Open Access
Citation
Journal of Extracellular Vesicles, 2023, v. 12, n. 9 How to Cite?
Abstract

γδ-T cells are innate-like T cells with dual antitumor activities. They can directly eradicate tumor cells and function as immunostimulatory cells to promote antitumor immunity. Previous studies have demonstrated that small extracellular vesicles (EVs) derived from γδ-T cells (γδ-T-EVs) inherited the dual antitumor activities from their parental cells. However, it remains unknown whether γδ-T-EVs can be designed as tumors vaccine to improve therapeutic efficacy. Here, we found that γδ-T-EVs had immune adjuvant effects on antigen-presenting cells, as revealed by enhanced expression of antigen-presenting and co-stimulatory molecules, secretion of pro-inflammatory cytokines and antigen-presenting ability of DCs after γδ-T-EVs treatment. The γδ-T-EVs-based vaccine was designed by loading tumor-associated antigens (TAAs) into γδ-T-EVs. Compared with γδ-T-EVs, the γδ-T-EVs-based vaccine effectively promoted more tumor-specific T-cell responses. In addition, the vaccine regimen preserved direct antitumor effects and induced tumor cell apoptosis. Interestingly, the allogeneic γδ-T-EVs-based vaccine showed comparable preventive and therapeutic antitumor effects to their autologous counterparts, indicating a better way of centralization and standardization in clinical practice. Furthermore, the allogeneic γδ-T-EVs-based vaccine displayed advantages over the DC-EVs-based vaccine through their dual antitumor activities. This study provides a proof-of-concept for using the allogeneic γδ-T-EVs-based vaccine in cancer control.


Persistent Identifierhttp://hdl.handle.net/10722/331611
ISSN
2023 Impact Factor: 15.5
2023 SCImago Journal Rankings: 4.268
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWang, Xiwei-
dc.contributor.authorZhang, Yanmei-
dc.contributor.authorChung, Yuet-
dc.contributor.authorTu, Chloe Ran-
dc.contributor.authorZhang, Wenyue-
dc.contributor.authorMu, Xiaofeng-
dc.contributor.authorWang, Manni-
dc.contributor.authorChan, Godfrey Chi‐Fung-
dc.contributor.authorLeung, Wing‐Hang-
dc.contributor.authorLau, Yu‐Lung-
dc.contributor.authorLiu, Yinping-
dc.contributor.authorTu, Wenwei-
dc.date.accessioned2023-09-21T06:57:21Z-
dc.date.available2023-09-21T06:57:21Z-
dc.date.issued2023-08-31-
dc.identifier.citationJournal of Extracellular Vesicles, 2023, v. 12, n. 9-
dc.identifier.issn2001-3078-
dc.identifier.urihttp://hdl.handle.net/10722/331611-
dc.description.abstract<p>γδ-T cells are innate-like T cells with dual antitumor activities. They can directly eradicate tumor cells and function as immunostimulatory cells to promote antitumor immunity. Previous studies have demonstrated that small extracellular vesicles (EVs) derived from γδ-T cells (γδ-T-EVs) inherited the dual antitumor activities from their parental cells. However, it remains unknown whether γδ-T-EVs can be designed as tumors vaccine to improve therapeutic efficacy. Here, we found that γδ-T-EVs had immune adjuvant effects on antigen-presenting cells, as revealed by enhanced expression of antigen-presenting and co-stimulatory molecules, secretion of pro-inflammatory cytokines and antigen-presenting ability of DCs after γδ-T-EVs treatment. The γδ-T-EVs-based vaccine was designed by loading tumor-associated antigens (TAAs) into γδ-T-EVs. Compared with γδ-T-EVs, the γδ-T-EVs-based vaccine effectively promoted more tumor-specific T-cell responses. In addition, the vaccine regimen preserved direct antitumor effects and induced tumor cell apoptosis. Interestingly, the allogeneic γδ-T-EVs-based vaccine showed comparable preventive and therapeutic antitumor effects to their autologous counterparts, indicating a better way of centralization and standardization in clinical practice. Furthermore, the allogeneic γδ-T-EVs-based vaccine displayed advantages over the DC-EVs-based vaccine through their dual antitumor activities. This study provides a proof-of-concept for using the allogeneic γδ-T-EVs-based vaccine in cancer control.<br></p>-
dc.languageeng-
dc.publisherWiley Open Access-
dc.relation.ispartofJournal of Extracellular Vesicles-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectextracellular vesicle-
dc.subjectimmunotherapy-
dc.subjecttumor-
dc.subjectvaccine-
dc.subjectγδ-T cells-
dc.titleTumor vaccine based on extracellular vesicles derived from γδ‐T cells exerts dual antitumor activities-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1002/jev2.12360-
dc.identifier.scopuseid_2-s2.0-85169363314-
dc.identifier.volume12-
dc.identifier.issue9-
dc.identifier.eissn2001-3078-
dc.identifier.isiWOS:001059424300001-
dc.identifier.issnl2001-3078-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats